Neuromotor ImpairmentsNCT07405450
Clinical Impacts of Structured Robotic Gait Training Programs
A study testing Clinical Impacts of Structured Robotic Gait Training Programs in people with Neuromotor Impairments and Walking Impairment, run by University of Calgary at 1 site in Canada.
Trial summary
Background and Rationale: Walking impairments impacts the 2-3/1000 children who have cerebral palsy1,2, and others unable to walk due to other central nervous system disorders such as a traumatic brain injury. The impacts of this and related impairment impact all aspects of life. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Neuromotor Impairments, Walking Impairment
- What is being tested?
- Clinical Impacts of Structured Robotic Gait Training Programs
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 120 participants
- Where
- 1 siteCanada
- Study dates
- 1 Nov 2022to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- able to fit into Trexo robotic gait trainer (both leg length and weight); height of <~5'6", weight <150 lbs.)
- able to fulfill training requirements throughout training period
- able to comply with study procedures (assessments, training)
- any age
Who cannot join
- those with contraindications to training with a robotic gait trainer (ie. medical condition or recent surgery requiring lower extremity immobilization or weight-bearing restriction (ie. fracture, unstable hip subluxation), medical condition requiring a physical activity restriction (ie. unstable arrythmia), pain or symptomatic hypotension while standing, contracture such that the Trexo Robotic Gait Training does not result in forward movement)
- those involved in a potentially confounding intervention (will be discussed case-by-case to determine risk of impacting the study results).
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Canada1 site, 1 recruiting
- Recruiting
Alberta Children's Hospital
Calgary, Alberta, T2N 1N4
Asmaa Affan, 403-955-5528, poni.lab@ucalgary.ca
About this study
Background and Rationale:
Walking impairments impacts the 2-3/1000 children who have cerebral palsy1,2, and others unable to walk due to other central nervous system disorders such as a traumatic brain injury. The impacts of this and related impairment impact all aspects of life. The lifelong costs of these is staggering in terms of dollars (over $1 million/child) and health adjusted life years (~half compared to typically developing populations despite only slightly shorter lifespans). Yet there are currently no effective interventions to treat the fundamental balance impairment that underlie these problems4,5. Early use of robotic gait trainers have shown many benefits6,7, however access to these trainers is limited due to cost, availability, and ease of use within the home. Currently, there are a few options for an overground robotic gait trainer supported by the stability of a walker. The Trexo, is an option designed for use at home or in a community settings, but barriers to access mean that access to this therapy is out of reach for many people who may see benefits.
Read more
Research Questions and Objectives:
The aim of this study is to (a) evaluate the feasibility of a clinical robotic gait training program and (b) evaluate the effectiveness of these types of programs in achieving patient, family, and therapist goals. The study will examine adherence to a structured training program to determine if training with a robotic gait trainer in a hospital setting is feasible for the entire length of the designed training program. Goals will be set, a re-evaluation of these goals will be completed following the training program to determine whether or not the clinical program of robotic gait training was successful in helping patients reach the goals set out at the beginning of the program.
Read the detailed description
Background and Rationale:
Walking impairments impacts the 2-3/1000 children who have cerebral palsy1,2, and others unable to walk due to other central nervous system disorders such as a traumatic brain injury. The impacts of this and related impairment impact all aspects of life. The lifelong costs of these is staggering in terms of dollars (over $1 million/child) and health adjusted life years (~half compared to typically developing populations despite only slightly shorter lifespans). Yet there are currently no effective interventions to treat the fundamental balance impairment that underlie these problems4,5. Early use of robotic gait trainers have shown many benefits6,7, however access to these trainers is limited due to cost, availability, and ease of use within the home. Currently, there are a few options for an overground robotic gait trainer supported by the stability of a walker. The Trexo, is an option designed for use at home or in a community settings, but barriers to access mean that access to this therapy is out of reach for many people who may see benefits.
Research Questions and Objectives:
The aim of this study is to (a) evaluate the feasibility of a clinical robotic gait training program and (b) evaluate the effectiveness of these types of programs in achieving patient, family, and therapist goals. The study will examine adherence to a structured training program to determine if training with a robotic gait trainer in a hospital setting is feasible for the entire length of the designed training program. Goals will be set, a re-evaluation of these goals will be completed following the training program to determine whether or not the clinical program of robotic gait training was successful in helping patients reach the goals set out at the beginning of the program.
Methods:
A prospective, single cohort pragmatic trial to examine the feasibility and utility of Trexo training at Alberta Children's Hospital will be conducted. Participants and their families/caregivers will work with a physiatrist and physiotherapist or kinesiologist with pediatric rehabilitation experience to develop goals and a reasonable training schedule. Clinical training programs will be unique to each participant based on goals and level of function. Consent will be obtained by a member of the research team. Researchers will make it clear that participation in the study is voluntary and that it will not have any effect on their care outside of this program. Participants will be able to provide their own consent if they are 14 years of age or older and have decision making capacity. Parental or guardian consent will be obtained if (i) the participant is 14 years of age or older without decision making capacity or (ii) the participant is younger than 14 years old. We will enroll as many participants into the study as possible within a 2 year time frame. The first visit will be used to determine eligibility, discuss goals, complete a baseline quality of life assessment, and complete an initial fitting. The second visit will be the initial assessment session. The purpose of this visit is to establish a functional baseline for participants before they start training. These will be tailored to each unique participant's goals. After these visits, training will begin. Training visits will be completed as outlined in this clinical program developed by the physiotherapist/kinesiologist. Duration and frequency of the program will depend on goals and feasibility of the training schedule. Following training, the follow-up assessment schedule will repeat the measures taken at the initial assessment session in order to evaluate the success of the training program. Outcome measures will include feasibility of training, usability of the Trexo as a training device, assessment of goals, and adverse events. Feasibility will be assessed by gathering data on therapist training hours, and usability will be assessed via therapist completion of System Usability Scale scoring at two-month intervals during the training period (the open access questionnaire is to be completed via Google Forms questionnaires). Quality of life impact will also be an outcome measure, assessed via the EQ-5D-Y questionnaire (to be administered via a combination of paper forms and electronic Redcap forms). Feasibility outcomes will be presented with descriptive statistics. Assessment of goals will be analyzed using the Wilcoxon signed-rank test for non-parametric difference of means in related samples. The remainder of the analysis plan will focus on descriptive statistics and parameter effect sizes.
- Conditions
- Neuromotor Impairments, Walking Impairment
- Being tested
- Clinical Impacts of Structured Robotic Gait Training Programs
- Keywords
- Robotic Walking, Trexo
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical Impacts of Structured Robotic Gait Training ProgramsDevice
All participants will participate in this arm involving 8 weeks of training 2-3 days/week using the Trexo walking device in clinic
| Study group | Role | What they receive |
|---|---|---|
| Clinical Impacts of Structured Robotic Gait Training Programs | Experimental | All participants will participate in this arm involving 8 weeks of training 2-3 days/week Receives: Device: Clinical Impacts of Structured Robotic Gait Training Programs |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of Sessions Attended
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the number of sessions attended by the participants.
Measured: Approximately 8 weeks
Number of Sessions Missed
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the number of sessions missed by the participants.
Measured: Approximately 8 weeks
Length of Session
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the length of each training session.
Measured: Approximately 8 weeks
Number of steps per session
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the number of steps taken by participants in each session.
Measured: Approximately 8 weeks
Clinician time per session
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the amount of time it takes clinicians to setup, run, and teardown for each training session
Measured: Approximately 8 weeks per participant enrolled.
Secondary outcomes (2)
Canadian Occupational Performance Measure (COPM)
Evaluate the effectiveness of these types of programs in achieving patient, family, and therapist goals, ranked on a 10-point scale (1-10) for performance and satisfaction.
Measured: Approximately 8 weeks
Goal Attainment Scaling (GAS)
Evaluate the effectiveness of these types of programs in achieving patient, family, and therapist goals, ranked on a 5-point scale from -2 to 2 where the midpoint (0) is typically set as baseline and changes are scored based on objectively measured outcomes.
Measured: Approximately 8 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2026
- Study start1 Nov 2022
- Primary completionMay 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Neuromotor ImpairmentsStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- All participants will complete robotic walking intervention only.
- Masking
- None (open label)
- Enrolment
- 120 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Calgary
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Elizabeth Condliffe, PhD MD, University of Calgary
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07405450
- Sponsor's protocol ID
- REB22-0511
- Status last verified
- Feb 2026
- First submitted
- 12 Dec 2025
- Last updated
- 12 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: There is an open science plan to share de-identified IPD. All data collected in the study will be de-identified and added to a database. Access by other researchers must be requested and agree to a Terms of Use agreement before access is granted.
Study at a glance
From the registry record, last updated by the sponsor on 12 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Impacts of Structured Robotic Gait Training Programs
- ClinicalTrials.gov ID
- NCT07405450
- Acronym / sponsor ID
- REB22-0511
- Conditions
- Neuromotor Impairments, Walking Impairment
- Keywords
- Robotic Walking, Trexo
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 120 participants (estimated)
- Lead sponsor
- University of CalgaryUniversity, hospital or other
- Study start
- 1 Nov 2022 (actual)
- Primary completion
- May 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 12 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Background and Rationale:
Walking impairments impacts the 2-3/1000 children who have cerebral palsy1,2, and others unable to walk due to other central nervous system disorders such as a traumatic brain injury. The impacts of this and related impairment impact all aspects of life. The lifelong costs of these is staggering in terms of dollars (over $1 million/child) and health adjusted life years (~half compared to typically developing populations despite only slightly shorter lifespans). Yet there are currently no effective interventions to treat the fundamental balance impairment that underlie these problems4,5. Early use of robotic gait trainers have shown many benefits6,7, however access to these trainers is limited due to cost, availability, and ease of use within the home. Currently, there are a few options for an overground robotic gait trainer supported by the stability of a walker. The Trexo, is an option designed for use at home or in a community settings, but barriers to access mean that access to this therapy is out of reach for many people who may see benefits.
Research Questions and Objectives:
The aim of this study is to (a) evaluate the feasibility of a clinical robotic gait training program and (b) evaluate the effectiveness of these types of programs in achieving patient, family, and therapist goals. The study will examine adherence to a structured training program to determine if training with a robotic gait trainer in a hospital setting is feasible for the entire length of the designed training program. Goals will be set, a re-evaluation of these goals will be completed following the training program to determine whether or not the clinical program of robotic gait training was successful in helping patients reach the goals set out at the beginning of the program.
Detailed description
Background and Rationale:
Walking impairments impacts the 2-3/1000 children who have cerebral palsy1,2, and others unable to walk due to other central nervous system disorders such as a traumatic brain injury. The impacts of this and related impairment impact all aspects of life. The lifelong costs of these is staggering in terms of dollars (over $1 million/child) and health adjusted life years (~half compared to typically developing populations despite only slightly shorter lifespans). Yet there are currently no effective interventions to treat the fundamental balance impairment that underlie these problems4,5. Early use of robotic gait trainers have shown many benefits6,7, however access to these trainers is limited due to cost, availability, and ease of use within the home. Currently, there are a few options for an overground robotic gait trainer supported by the stability of a walker. The Trexo, is an option designed for use at home or in a community settings, but barriers to access mean that access to this therapy is out of reach for many people who may see benefits.
Research Questions and Objectives:
The aim of this study is to (a) evaluate the feasibility of a clinical robotic gait training program and (b) evaluate the effectiveness of these types of programs in achieving patient, family, and therapist goals. The study will examine adherence to a structured training program to determine if training with a robotic gait trainer in a hospital setting is feasible for the entire length of the designed training program. Goals will be set, a re-evaluation of these goals will be completed following the training program to determine whether or not the clinical program of robotic gait training was successful in helping patients reach the goals set out at the beginning of the program.
Methods:
A prospective, single cohort pragmatic trial to examine the feasibility and utility of Trexo training at Alberta Children's Hospital will be conducted. Participants and their families/caregivers will work with a physiatrist and physiotherapist or kinesiologist with pediatric rehabilitation experience to develop goals and a reasonable training schedule. Clinical training programs will be unique to each participant based on goals and level of function. Consent will be obtained by a member of the research team. Researchers will make it clear that participation in the study is voluntary and that it will not have any effect on their care outside of this program. Participants will be able to provide their own consent if they are 14 years of age or older and have decision making capacity. Parental or guardian consent will be obtained if (i) the participant is 14 years of age or older without decision making capacity or (ii) the participant is younger than 14 years old. We will enroll as many participants into the study as possible within a 2 year time frame. The first visit will be used to determine eligibility, discuss goals, complete a baseline quality of life assessment, and complete an initial fitting. The second visit will be the initial assessment session. The purpose of this visit is to establish a functional baseline for participants before they start training. These will be tailored to each unique participant's goals. After these visits, training will begin. Training visits will be completed as outlined in this clinical program developed by the physiotherapist/kinesiologist. Duration and frequency of the program will depend on goals and feasibility of the training schedule. Following training, the follow-up assessment schedule will repeat the measures taken at the initial assessment session in order to evaluate the success of the training program. Outcome measures will include feasibility of training, usability of the Trexo as a training device, assessment of goals, and adverse events. Feasibility will be assessed by gathering data on therapist training hours, and usability will be assessed via therapist completion of System Usability Scale scoring at two-month intervals during the training period (the open access questionnaire is to be completed via Google Forms questionnaires). Quality of life impact will also be an outcome measure, assessed via the EQ-5D-Y questionnaire (to be administered via a combination of paper forms and electronic Redcap forms). Feasibility outcomes will be presented with descriptive statistics. Assessment of goals will be analyzed using the Wilcoxon signed-rank test for non-parametric difference of means in related samples. The remainder of the analysis plan will focus on descriptive statistics and parameter effect sizes.
Study design
- Primary purpose
- Health services research
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- All participants will complete robotic walking intervention only.
| Arm | Type | Receives |
|---|---|---|
| Clinical Impacts of Structured Robotic Gait Training Programs | Experimental | Device: Clinical Impacts of Structured Robotic Gait Training ProgramsAll participants will participate in this arm involving 8 weeks of training 2-3 days/week |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- able to fit into Trexo robotic gait trainer (both leg length and weight); height of <~5'6", weight <150 lbs.)
- able to fulfill training requirements throughout training period
- able to comply with study procedures (assessments, training)
- any age
Key exclusion criteria (2 listed)
- those with contraindications to training with a robotic gait trainer (ie. medical condition or recent surgery requiring lower extremity immobilization or weight-bearing restriction (ie. fracture, unstable hip subluxation), medical condition requiring a physical activity restriction (ie. unstable arrythmia), pain or symptomatic hypotension while standing, contracture such that the Trexo Robotic Gait Training does not result in forward movement)
- those involved in a potentially confounding intervention (will be discussed case-by-case to determine risk of impacting the study results).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical Impacts of Structured Robotic Gait Training ProgramsAll participants will participate in this arm involving 8 weeks of training 2-3 days/week using the Trexo walking device in clinic | Device | Clinical Impacts of Structured Robotic Gait Training Programs |
Primary outcome
Number of Sessions Attended
Time frame: Approximately 8 weeks
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the number of sessions attended by the participants.
Number of Sessions Missed
Time frame: Approximately 8 weeks
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the number of sessions missed by the participants.
Length of Session
Time frame: Approximately 8 weeks
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the length of each training session.
Number of steps per session
Time frame: Approximately 8 weeks
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the number of steps taken by participants in each session.
Clinician time per session
Time frame: Approximately 8 weeks per participant enrolled.
Evaluate the feasibility of using a robotic gait trainer in an out-patient setting by tracking the amount of time it takes clinicians to setup, run, and teardown for each training session
2 secondary outcomes
Canadian Occupational Performance Measure (COPM)
Time frame: Approximately 8 weeks
Goal Attainment Scaling (GAS)
Time frame: Approximately 8 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Feb 2026.
- Individual participant dataSharing planned: Yes. There is an open science plan to share de-identified IPD. All data collected in the study will be de-identified and added to a database. Access by other researchers must be requested and agree to a Terms of Use agreement before access is granted.
Related trials for Neuromotor Impairments
Not yet recruiting
PhiCube for Bilateral Upper Limb Neuromotor and Cognitive Rehabilitation in Adults
Stroke, Parkinson Disease
Not yet recruiting
AI-based Model for Rehabilitation Engagement and Motor Performance Evaluation in Pediatric Patients: A Pilot Study
Neuromotor Impairments
Recruiting
Physical Therapy for Montana Children With NMD Using Hippotherapy and the Equine Environment
Neuromotor Impairments
Recruiting
A Story for Pepper & Nao
Children and Adolescents With Neuromotor Impairment
Not yet recruiting
Assessment of Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments
Stroke, TBI
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Clinical Impacts of Structured Robotic Gait Training Programs in people with Neuromotor Impairments and Walking Impairment, run by University of Calgary at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 12 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Christa Diot (403-955-5528, poni.lab@ucalgary.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of Sessions Attended (time frame: Approximately 8 weeks). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Feb 2026.